These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31325529)

  • 1. Pro-differentiating and radiosensitizing effects of inhibiting HDACs by PXD-101 (Belinostat) in in vitro and in vivo models of human rhabdomyosarcoma cell lines.
    Marampon F; Di Nisio V; Pietrantoni I; Petragnano F; Fasciani I; Scicchitano BM; Ciccarelli C; Gravina GL; Festuccia C; Del Fattore A; Tombolini M; De Felice F; Musio D; Cecconi S; Tini P; Maddalo M; Codenotti S; Fanzani A; Polimeni A; Maggio R; Tombolini V
    Cancer Lett; 2019 Oct; 461():90-101. PubMed ID: 31325529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells.
    Cassandri M; Pomella S; Rossetti A; Petragnano F; Milazzo L; Vulcano F; Camero S; Codenotti S; Cicchetti F; Maggio R; Festuccia C; Gravina GL; Fanzani A; Megiorni F; Catanoso M; Marchese C; Tombolini V; Locatelli F; Rota R; Marampon F
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Romidepsin (FK228) fails in counteracting the transformed phenotype of rhabdomyosarcoma cells but efficiently radiosensitizes, in vitro and in vivo, the alveolar phenotype subtype.
    Rossetti A; Petragnano F; Milazzo L; Vulcano F; Macioce G; Codenotti S; Cassandri M; Pomella S; Cicchetti F; Fasciani I; Antinozzi C; Di Luigi L; Festuccia C; De Felice F; Vergine M; Fanzani A; Rota R; Maggio R; Polimeni A; Tombolini V; Gravina GL; Marampon F
    Int J Radiat Biol; 2021; 97(7):943-957. PubMed ID: 33979259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma.
    Ghayad SE; Rammal G; Sarkis O; Basma H; Ghamloush F; Fahs A; Karam M; Harajli M; Rabeh W; Mouawad JE; Zalzali H; Saab R
    Cancer Biol Ther; 2019; 20(3):272-283. PubMed ID: 30307360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OBP‑801, a novel histone deacetylase inhibitor, induces M‑phase arrest and apoptosis in rhabdomyosarcoma cells.
    Tomoyasu C; Kikuchi K; Kaneda D; Yagyu S; Miyachi M; Tsuchiya K; Iehara T; Sakai T; Hosoi H
    Oncol Rep; 2019 Jan; 41(1):643-649. PubMed ID: 30365145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumour effects of SFX-01 molecule in combination with ionizing radiation in preclinical and in vivo models of rhabdomyosarcoma.
    Camero S; Milazzo L; Vulcano F; Ceccarelli F; Pontecorvi P; Pedini F; Rossetti A; Scialis ES; Gerini G; Cece F; Pomella S; Cassandri M; Porrazzo A; Romano E; Festuccia C; Gravina GL; Ceccarelli S; Rota R; Lotti LV; Midulla F; Angeloni A; Marchese C; Marampon F; Megiorni F
    BMC Cancer; 2024 Jul; 24(1):814. PubMed ID: 38977944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
    Nguyen T; Parker R; Hawkins E; Holkova B; Yazbeck V; Kolluri A; Kmieciak M; Rahmani M; Grant S
    Oncotarget; 2017 May; 8(19):31478-31493. PubMed ID: 28416758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
    Chien W; Lee DH; Zheng Y; Wuensche P; Alvarez R; Wen DL; Aribi AM; Thean SM; Doan NB; Said JW; Koeffler HP
    Mol Carcinog; 2014 Sep; 53(9):722-35. PubMed ID: 23475695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical role of mitochondria-mediated apoptosis for JNJ-26481585-induced antitumor activity in rhabdomyosarcoma.
    Heinicke U; Kupka J; Fichter I; Fulda S
    Oncogene; 2016 Jul; 35(28):3729-41. PubMed ID: 26616861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anti-tumor growth effect of a novel agent DMAMCL in rhabdomyosarcoma in vitro and in vivo.
    Xu N; Hua Z; Ba G; Zhang S; Liu Z; Thiele CJ; Li Z
    J Exp Clin Cancer Res; 2019 Mar; 38(1):118. PubMed ID: 30850026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer.
    Chan D; Zheng Y; Tyner JW; Chng WJ; Chien WW; Gery S; Leong G; Braunstein GD; Koeffler HP
    J Cancer Res Clin Oncol; 2013 Sep; 139(9):1507-14. PubMed ID: 23824064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
    Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C
    Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition.
    Blattmann C; Oertel S; Ehemann V; Thiemann M; Huber PE; Bischof M; Witt O; Deubzer HE; Kulozik AE; Debus J; Weber KJ
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):237-45. PubMed ID: 20646843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone Deacetylase Inhibitors Inhibit Rhabdomyosarcoma by Reactive Oxygen Species-Dependent Targeting of Specificity Protein Transcription Factors.
    Hedrick E; Crose L; Linardic CM; Safe S
    Mol Cancer Ther; 2015 Sep; 14(9):2143-53. PubMed ID: 26162688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma.
    Havas AP; Rodrigues KB; Bhakta A; Demirjian JA; Hahn S; Tran J; Scavello M; Tula-Sanchez AA; Zeng Y; Schmelz M; Smith CL
    Cancer Biol Ther; 2016 Dec; 17(12):1240-1252. PubMed ID: 27791595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear receptor 4A1 (NR4A1) as a drug target for treating rhabdomyosarcoma (RMS).
    Lacey A; Hedrick E; Li X; Patel K; Doddapaneni R; Singh M; Safe S
    Oncotarget; 2016 May; 7(21):31257-69. PubMed ID: 27144436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis.
    Huang YC; Huang FI; Mehndiratta S; Lai SC; Liou JP; Yang CR
    Oncotarget; 2015 Jul; 6(21):18590-601. PubMed ID: 26087180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma.
    Hanna JA; Garcia MR; Go JC; Finkelstein D; Kodali K; Pagala V; Wang X; Peng J; Hatley ME
    Cell Death Dis; 2016 Jun; 7(6):e2256. PubMed ID: 27277678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells.
    Ciccarelli C; Marampon F; Scoglio A; Mauro A; Giacinti C; De Cesaris P; Zani BM
    Mol Cancer; 2005 Dec; 4():41. PubMed ID: 16351709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.